Conferences

ecancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.
Share :

AACR Annual Meeting 2022

Giving abatacept after checkpoint inhibitors can improve immunotherapy responses in melanoma

Dr Stephen Mok - The University of Texas MD Anderson Cancer Center, Houston, USA
Giving abatacept after checkpoint inhibitors can improve immunotherapy responses in melanoma ( Dr Stephen Mok - The University of Texas MD Anderson Cancer Center, Houston, USA )
19 May 2022

Long-term outcomes with sotorasib in pretreated KRASp.G12C-mutated NSCLC: 2-year analysis of CodeBreaK100

Dr Grace Dy - Roswell Park Comprehensive Cancer Center, Buffalo, USA
Long-term outcomes with sotorasib in pretreated KRASp.G12C-mutated NSCLC: 2-year analysis of CodeBreaK100 ( Dr Grace Dy - Roswell Park Comprehensive Cancer Center, Buffalo, USA )
10 May 2022

Nivolumab plus platinum-doublet chemo vs chemo as neoadjuvant treatment for resectable NSCLC

Prof Nicolas Girard - Institut Curie, Paris, France
Nivolumab plus platinum-doublet chemo vs chemo as neoadjuvant treatment for resectable NSCLC ( Prof Nicolas Girard - Institut Curie, Paris, France )
10 May 2022

Natural killer cells complexed with a bispecific antibody may provide new treatment option for patients with advanced lymphoma

Prof Yago Nieto - The University of Texas MD Anderson Cancer Center, Houston, USA
Natural killer cells complexed with a bispecific antibody may provide new treatment option for patients with advanced lymphoma ( Prof Yago Nieto - The University of Texas MD Anderson Cancer Center, Houston, USA )
26 Apr 2022

Intratumoral BO-112 with pembrolizumab shows benefit in advanced melanoma refractory to anti-PD-1 therapy

Dr Iván Márquez-Rodas - Hospital General Universitario Gregorio Marañón, Madrid, Spain
Intratumoral BO-112 with pembrolizumab shows benefit in advanced melanoma refractory to anti-PD-1 therapy ( Dr Iván Márquez-Rodas - Hospital General Universitario Gregorio Marañón, Madrid, Spain )
21 Apr 2022

Recurrent non-invasive breast tumours may not always be related to the primary lesion

Dr Tanjina Kader - University of Melbourne, Melbourne, Australia
Recurrent non-invasive breast tumours may not always be related to the primary lesion ( Dr Tanjina Kader - University of Melbourne, Melbourne, Australia )
19 Apr 2022

Safety and efficacy of olaparib plus metronomic cyclophosphamide and metformin in advanced/metastatic endometrial cancer

Prof Benoit You - Hospices Civils de Lyon, Lyon, France
Safety and efficacy of olaparib plus metronomic cyclophosphamide and metformin in advanced/metastatic endometrial cancer ( Prof Benoit You - Hospices Civils de Lyon, Lyon, France )
14 Apr 2022

Novel bispecific checkpoint inhibitor MEDI5752 shows promise for advanced solid tumours

Dr Ben Tran - Peter MacCallum Cancer Centre, Melbourne, Australia
Novel bispecific checkpoint inhibitor MEDI5752 shows promise for advanced solid tumours ( Dr Ben Tran - Peter MacCallum Cancer Centre, Melbourne, Australia )
14 Apr 2022

The adverse events atlas, towards a strategy to predict synergistic adverse events of combination therapies

Prof Bart Westerman - Amsterdam UMC, Amsterdam, Netherlands
The adverse events atlas, towards a strategy to predict synergistic adverse events of combination therapies ( Prof Bart Westerman - Amsterdam UMC, Amsterdam, Netherlands )
13 Apr 2022

Safety and efficacy of the oral ATR inhibitor elimusertib in advanced solid tumours with DNA damage response defects

Dr Timothy Yap - MD Anderson Cancer Center, Houston, USA
Safety and efficacy of the oral ATR inhibitor elimusertib in advanced solid tumours with DNA damage response defects ( Dr Timothy Yap - MD Anderson Cancer Center, Houston, USA )
13 Apr 2022

PETRA: Next generation PARP1-selective inhibitor AZD5305 in patients with BRCA1/2, PALB2 or RAD51C/D mutations

Dr Timothy Yap - MD Anderson Cancer Center, Houston, USA
PETRA: Next generation PARP1-selective inhibitor AZD5305 in patients with BRCA1/2, PALB2 or RAD51C/D mutations ( Dr Timothy Yap - MD Anderson Cancer Center, Houston, USA )
13 Apr 2022

Novel COVID-19 vaccine for B-cell deficient patients

Prof Juliane Walz - University Hospital Tübingen, Tübingen, Germany
Novel COVID-19 vaccine for B-cell deficient patients ( Prof Juliane Walz - University Hospital Tübingen, Tübingen, Germany )
12 Apr 2022

Paediatric cancer patients in LMICS faced significantly higher mortality risk during the COVID-19 pandemic

Dr Muhammed Elhadi - University of Tripoli, Tripoli, Libya
Paediatric cancer patients in LMICS faced significantly higher mortality risk during the COVID-19 pandemic ( Dr Muhammed Elhadi - University of Tripoli, Tripoli, Libya )
11 Apr 2022